Artelo Biosciences
ARTL
1 hedge funds and large institutions have $0 invested in Artelo Biosciences in 2020 Q3 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and 2 closing their positions.
0% less ownership
Funds ownership: 0% → 0% (-0%)
50% less funds holding
Funds holding: 2 → 1 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
100% less capital invested
Capital invested by funds: $18K → $0 (-$18K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$284 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$17K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Goldman Sachs
New York
| – | -$17K | -53 | Closed |
|
|
TRCT
2
Tower Research Capital (TRC)
New York
| – | -$1K | -3 | Closed |
|
|
3
Morgan Stanley
New York
| – | +$284 | +1 | New |
|
ARTL Hedge Fund Activity: Q3 2020 in Review
1 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in Artelo Biosciences (ARTL) for Q3 2020, worth a combined $0 — down 100% from $18K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of ARTL and 1 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest buyer was Morgan Stanley, opening a new position worth an estimated $284. The largest seller was Goldman Sachs, exiting entirely with an estimated $17K sold.
- 1 institutional investor held Artelo Biosciences (ARTL) as of Q3 2020, down from 2 in Q2 2020.
- Funds reported $0 of Artelo Biosciences stock for Q3 2020, down 100% quarter-over-quarter.
- 1 fund opened new Artelo Biosciences positions in Q3 2020 and 2 closed out, a net change of -1 holder.
- The largest Artelo Biosciences buyer in Q3 2020 was Morgan Stanley, an estimated $284 added.
- The largest Artelo Biosciences seller in Q3 2020 was Goldman Sachs, an estimated $17K sold.
Based on aggregated 13F filings for Q3 2020.